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ABSTRACT
Introduction. The rapid spread of COVID-19 across the
globe is forcing surgical oncologists to change their daily
practice. We sought to evaluate how breast surgeons are
adapting their surgical activity to limit viral spread and
spare hospital resources.
Methods. A panel of 12 breast surgeons from the most
affected regions of the world convened a virtual meeting
the 7th of April 2020 to discuss the changes in their local
surgical practice during the COVID-19 pandemic. Similarly, a
web-based poll based was created to evaluate changes in
surgical practice among breast surgeons from several
countries.
Results. The virtual meeting showed that distinct countries
and regions were experiencing different phases of the pan-
demic. Surgical priority was given to patients with
aggressive disease not candidate for primary systemic ther-
apy, those with progressive disease under neoadjuvant sys-
temic therapy, and post-neoadjuvant patients. One hundred
breast surgeons filled out the poll. The trend showed reduc-
tions in operating room schedules, indications for surgery,
and consultations, with an increasingly restrictive approach
to elective surgery with worsening of the pandemic.
Conclusion. The COVID-19 emergency should not compro-
mise treatment of a potentially lethal disease such as breast
cancer. Our results reveal that physicians are instinctively
reluctant to abandon conventional standards of care when
possible. However, as the situation deteriorates, alternative
strategies of de-escalation are being adopted. The
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Breast Cancer
Implications for Practice: Our study aims to characterize how the COVID-19 pandemic is affecting breast cancer surgery and
which strategies are being adopted to cope with the situation.
BACKGROUND
The COVID-19 pandemic is affecting health resources on a
global scale with a significant impact on oncological man-
agement1. Clinicians must balance standard cancer thera-
pies with measures designed to limit the spread of COVID-
19. At the same time, healthcare workers face many chal-
lenges including shortage of resources (e.g. personal protec-
tive equipment), excessive working hours and psychological
distress2-4.
Breast cancer (BC) is a common disease affecting 1 in
8 western women and is potentially lethal5. For the major-
ity of early stage patients, surgery remains the primary
treatment, but delays from diagnosis to start of treatment
of less than 90 days does not appear to adversely impact
prognosis6. This rule, however, does not apply to all clinical
scenarios and patients who need surgery more urgently
should be identified through appropriate and effective tri-
age7. Decisions on treatment must take into account the
individual risk of exposure and infection and balance it with
the potential risk of a worse oncological outcome if the
appropriate treatment is not commenced in a timely
fashion.
According to World Health Organization (WHO), social
distancing, quarantine (for asymptomatic COVID-19-positive
patients, people who came in contact with COVID-19 posi-
tive patients and people coming from areas with high num-
ber of COVID-19 cases) and wearing face masks when in
proximity to others are the most effective measures to con-
trol the spread of COVID-19. These measures can help to
slow down the rate of new infections, allowing healthcare
systems to cope with clinical demand and allocate sufficient
resources in the quest for an effective therapy and continu-
ing ongoing research8,9.
However, the combination of social distancing and
reduced resources may clash with the surgical management
of breast cancer patients.
This study aims to examine the changes in the surgical
management of breast cancer patients during the different
phases of the COVID-19 pandemic. . Results of this study
will provide better understanding of how healthcare sys-
tems rapidly adapt to a new crisis and highlight key ele-
ments for planning the recovery phase.
MATERIALS AND METHODS
G.Re.T.A. (Group for Reconstructive and Therapeutic
Advancements), is an international organization founded in
2017 that aims to bring together breast cancer specialists in
order to advance multidisciplinary educational and research
activity10. The organization convened a virtual meeting enti-
tled “the surgical management of breast cancer during the
COVID-19 emergency”. A web-based poll designed to
explore the different approaches and responses during the
COVID-19 pandemic was launched 3 days prior to the
scheduled meeting.
Virtual meeting
A panel of 12 dedicated breast surgeons from 9 countries
across three continents were invited to participate in a vir-
tual meeting held on the 7th of April at 4.00 PM GMT+1.
The panel included breast surgeons from those areas most
affected at the time by COVID-19 (Iran, Italy, Spain, UK, and
USA) together with other specialists from China, Denmark,
Portugal, Sweden, and Switzerland.
All panel members were invited as spokespersons for
their respective multidisciplinary team.
In addition, an experienced medical oncologist (CC) was
invited to contribute and supervise the multidisciplinary dis-
cussion. Panelists discussed the following topics in accor-
dance with corresponding national and local/institutional
guidelines:
a) Pandemic phase according to American College of
Surgeons7
b) Triage and management of new breast clinic referrals
and breast cancer diagnoses
c) Surgical priorities
d) Alternatives to surgery
e) Management of admitted patients (including operat-
ing room)
f) Management/Modalities of consultations
The virtual meeting was advertised through the G.Re.T.
A institutional website and on social media. Ninety partici-
pants joined the meeting.
Web-based poll
An anonymous web-based poll was set up on the 4th of
April 2020, and all the panelists and the participants to the
virtual meeting were invited to participate. The poll was
also circulated through G.Re.T.A. social media in order to
reach the largest scheduled number of participants. The
poll was based on the “American College of Surgeons:
COVID-19 Elective Case Triage Guidelines for Surgical Care
of Breast Cancer” issued on the 24th of March 2020 by the
ACS and available on-line7 (ACS weblink) (Supplemental
material 1).
ICU Intensive Care Unit
The questionnaire included eight items (Supplemental
material 2):
• Geographical area
• Position of participant
• Pandemic phase according to the aforementioned
guidelines
• Priorities in breast cancer surgical management (cases to
be done as soon as possible)
• Cases that can be deferred
• Alternative treatment approaches to be considered
• Modalities of consultations/long term follow-up
© AlphaMed Press 2020
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• Operating room schedule
Due to the rapid evolution of the pandemic, a pre-
specified number of total participants was fixed at 100. The
poll closed on April 14th after reaching the pre-
specified goal.
Data Analysis
Replies were grouped according to geographical area
experiencing a similar phase of the pandemic . Replies to
topic d-e-f-g-h are listed according to progressive restric-
tions. Due to the reduced sample size and in order to per-
form statistical analysis, we grouped variables to become
bivariate (i.e. standard vs. restricted modalities)
(Supplemental material 3). Response rates were compared
among groups using Fisher’s exact test. P-values < 0.05
were considered statistically significant. Statistical analysis




On of the meeting day, different countries and regions were
in different phases of the pandemic11, and therefore partici-
pants were in different ACS phases. This was true also
within the same country and within large cities.
Differences were observed in the surgical management
of BC among panelists from different countries, and from
different institutions within the same country (private
vs. public hospitals, academic or tertiary care) and are sum-
marized in Table 1. In some countries multiple guidelines
and consensus statements issued from different scientific
societies and institutions were available7,12-14, whereas in
other countries equally affected, no specific breast surgery
related guidelines had been released by entitled entities.
The lockdown starting date varied from 23rd January
2020 in China (where it was already concluded at the time
of the meeting) to 29th March (Spain). Notably, this mea-
sure was not applied in Sweden, where social distancing
was voluntary.
BC screening programs were halted in most countries,
except for Sweden and Denmark. Most of the countries in
phase 2-3 had implemented a triage system (the day before
or the day of admission), that took place at the hospital or
via tele-consultation in advance of any face-to-face (FTF)
encounter (UK/USA). Screening methods varied between
and within countries, ranging from clinical history only, to
temperature assessment with screening and SpO2 check
and nasopharyngeal swabs with chest X-ray/CT-scan. Naso-
pharyngeal swabs with negative results were mandatory
before surgery in Spain, Portugal, Switzerland and in Italy
(with variations according to local institution policy). In
other countries, polymerase chain reaction testing on swabs
were indicated only for symptomatic patients (Italy, UK,
Sweden, Denmark). Allocation of single rooms was routinely
adopted in China and the use of masks by patients was
strongly recommended in all countries.
Same day discharge policy wherever possible was pre-
ferred although not mandatory (Italy, Spain, UK, Sweden,
Denmark and in the USA).
Surgical prioritization varied between countries and
according to the phase of the pandemic. China had
resumed standard clinical practice, whereas Italy, the USA
and UK were prioritizing urgent cancer cases in anticipation
of the need for intensive care unit (ICU) facilities. Priorities
for surgery included patients with progressive disease while
on neoadjuvant chemotherapy (NAC), post-NAC patients,
patients with small triple negative (TN) and human epider-
mal growth factor (HER2) positive, or T2 N0 hormone
receptor (HR) positive /HER2- not deemed eligible for neo-
adjuvant treatment cases (Italy). In Italy/Spain/UK, ductal
carcinoma in situ (DCIS) patients were not considered a pri-
ority and could be deferred (Italy >8 weeks) depending on
ventilator availability. In the USA/UK, receptor status testing
was recommended for all cases of DCIS and endocrine ther-
apy was recommended for hormone HR+ DCIS12,13. There
was consensus across countries that primary systemic treat-
ment was an acceptable alternative strategy to defer surgi-
cal excision and should be based on national/international
guidelines. In both the UK/USA, it was considered accept-
able to defer surgery by commencing primary endocrine
treatment in patients with HR+/HER2-, node negative
tumors. Due to the broadening of indications for preopera-
tive therapy, genomic (or Ki-67/grade) testing of core biopsy
material was discretionary for some higher risk tumors.
The majority of panelists deferred immediate breast
reconstruction (IBR), especially more complex autologous
flap-based procedures, yet most considered two stage
implant-based IBR a safe and manageable option.
Web-based poll
A total of 100 breast surgeons completed the poll, with the
majority (90%) being fully accredited surgeons and only
10% trainees. Two-thirds of respondents (63%) worked in a
Phase 1 setting with relatively few COVID-19 patients and
availability of ICU beds. Just over one-third were based in
the most severely affected European areas (Italy, Spain,
France and UK), with just 19% from South America, 8% from
Iran and the remaining 35% from other countries.
The poll revealed a general contraction of breast surgi-
cal capacity across the world as seen in Figure 1.
As the pandemic worsened with increasing demand for
ICU and ventilator facilities, there was a gradual shift from
elective to emergency surgery only (Figure 2).
Similarly, the total number of FTF consultations fell
across all countries surveyed (Figure 3) with suspension of
routine follow-up visits and acceptance of urgent referrals
only in more than three-quarters of units in phase 1 (84%)
and all those (100%) in phase 3.
Just over half of respondents (52%) prioritized surgery
following NAC, for T2 N1 HR+/HER2- cancers, for discordant
biopsies likely to be malignant, and for excision of malig-
nant recurrence.
There was a statistically significant association between
the level of surgical restriction and the pandemic phase
(p = 0.001), as shown in Figure 4.
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Overall, the great majority (88%) of surgeons deferred
benign cases, bilateral procedures and autologous recon-
structive surgery (Figure 5). With progression of the pan-
demic from phase 1 to 3, surgeons also deferred in situ HR+
disease as well as re-excision cases.
Almost half (48%) of respondents offered primary sys-
temic treatments as an alternative to surgery for the follow-
ing categories of tumor:
• T1N0 HR+/HER2- : endocrine therapy
• TN and HER2+ tumors: neo-adjuvant chemotherapy +/-
single/dual anti HER2 agents
• some T2 or N1 HR+/HER2- cancers: endocrine therapy
• N1 cancer irrespective of subtype: neo-adjuvant
chemotherapy
This approach was more likely to be adopted by partici-
pants with increasing severity of the COVID-19 pandemic
(40% in phase 1, 62% in phase 2 and 67% in phase 3). Four-
teen and 8% of participants in phases 1 and 2, respectively,
did not change their clinical decision-making process in
regard to neo-adjuvant treatments (Figure 6).
DISCUSSION
Resources and surgical management
Changes in the management of newly diagnosed breast
cancer in response to COVID-19 varied according to geo-
graphic area and pandemic phase, but also between differ-
ent institutions within a particular country. The
unprecedented speed and scale of the outbreak precluded
the establishment of any formal guidelines based on inter-
national consensus.
Our survey confirms a global reduction in the volume of
elective breast surgery that may be attributable to either a
shortage of facilities and limited surgical capacity during the
crisis or possibly to social distancing imposed by health
authorities with resultant limited access to healthcare in
general.
In principle, patients are prioritized for surgery based on
completion of neo-adjuvant chemotherapy, small (T1/N0)
TNBC or HER2 subtypes and T2 or N1 HR+/HER2- tumors. In
the event of a shortage of ventilatory and operating room
capacity, a crucial question is how long surgical manage-
ment can be deferred without impairment of clinical out-
comes. In a joint analysis of the Surveillance, Epidemiology,
and End Results (SEER)-Medicare-linked database and the
National Cancer Database (NCDB), delays of more than
90 days from diagnosis to treatment have been shown to
be associated with reduction in overall survival rates of
3.1-4.6%6. By implication, it might therefore be considered
appropriate to schedule surgery for within 90 days if no
other treatment is commenced as primary therapy.
However, when breast surgery is performed its impact
on the healthcare system is relatively modest; there are rel-
atively short operating times and limited need for intensive
care facilities with much surgery being performed as a day
case procedure with few complications. The re-admission
rate for complications following breast surgery as estimated
by the American College of Surgeons-National Surgical
Quality Improvement Program (ACS-NSQIP) database is
approximately 4% within 30 days15. The post-surgical ICU
admission rate after breast surgery is estimated 1.8% and
not comparable to major surgery16. Few complications fol-
lowing breast surgery mean also less patients coming back
to hospital for post-surgical consultation or secondary pro-
cedures, and consequently less urban mobility both of
patients and care-givers.
Our survey confirms that theatre lists can be managed
with relatively few resources and breast surgeons tend to
use any residual capacity to operate (even in phase 2).
Special considerations apply to immediate breast recon-
struction (IBR) and these are very much dependent on local
circumstances and operative capacity. Increased complica-
tion rates are associated with IBR (14.2% for implant-based
and 15.4% for autologous compared with 4.2% without IBR)
and this has prompted some countries to limit all forms of
IBR and in particular stop autologous tissue-based recon-
struction17. For younger patients wishing to preserve the
skin envelope, a “babysitter implant” or a formal epi-
pectoral approach may be an option but might lead to addi-
tional post-operative visits and potential re-admission to
hospital. Most of the participants deferred bilateral proce-
dures (such as most of stage II of tissue-expander/implant
reconstructions), or autologous reconstructions. According
to the poll and during phase progression more restrictive
indications prevented also re-excisions and excision biopsy
of uncertain lesions.
Alternatives to surgery
With the unprecedented circumstances of the COVID-19
pandemic in which there are potential shortages of ventila-
tor equipment and ICU personnel, professional bodies have
recommended alternative therapeutic options as a short-
term imperative. These are not necessarily based on publi-
shed data but reliant on “educated assumptions and expert
opinion”18.
The panel relayed information on national and institu-
tional recommendations for COVID-19 protocols with sev-
eral links available to association websites7,12,13,19. The ACS
triage, for instance is recommending 6-12 months of pri-
mary endocrine treatment in luminal A or Oncotype DX
<25% tumors7. However, before the current pandemic the
NCCN guidelines supported use of primary endocrine ther-
apy mainly in patients with co-morbidities and low risk ER+
invasive breast cancer20. Historically, this treatment has
been used for elderly patients with co-morbidities who
were considered unfit for surgery21-23. Concerns exist
regarding pre-operative endocrine therapy for pre-
menopausal women or for those with longer life expec-
tancy24. The ideal duration of pre-operative endocrine
treatment is unclear, but usually it should be given for at
least 6 months and in case of lack of response, surgery
should be carried out25-27. In some countries, primary endo-
crine therapy is also advised for HR+ DCIS, and hence all
core biopsies should be tested for HR12,13. These
approaches are in line with trials investigating non-
operative management of low risk DCIS where primary
endocrine therapy may be an option in the observation
arm28-30. Nonetheless, observation alone can be considered
for smaller low-risk DCIS irrespective of HR status and
© AlphaMed Press 2020
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pending operative availability12. Outcomes for DCIS man-
aged without loco-regional intervention were investigated
using the SEER database and low rates of progression to
invasive disease was demonstrated. However, results may
have been confounded by concurrent use of systemic endo-
crine treatment in some patients31.
The poll revealed that a sizable proportion of partici-
pants considered primary chemotherapy to be routine for
many patients with specific subtypes of breast cancer,
namely TNBC and HER2+. This practice could be extended
to all N1 patients irrespective of HR status, and to some
larger T2 HR+,/HER2- cancers. Indeed, a trend for broaden-
ing indications for primary systemic therapy was evident
with increasing gravity of the pandemic and pressure upon
emergency services.
Some experts according to national societies are
suggesting to use genomic testing pre-operatively to iden-
tify HR+/HER2- cancers which may be chemo-sensitive in
order to defer surgery and give NAC irrespective of tumor
stage32.
Some experts, conversely, report a particular concern
about the risk of COVID-19 infection, due to immunosup-
pression, for patients undergoing chemotherapy. This had
led some countries to restrict, instead of expanding, the
indications to neoadjuvant chemotherapy for patients with
early stage disease13.
Management of screening, outpatient workload and
referrals
Universal suspension of breast cancer screening services
has been reported from around the world. Depending on
the duration of shutdown, there may or may not be any
clinically meaningful impact on breast cancer mortality. It is
also unclear whether during the recovery phase, rules of
social distancing will impact on the number of women
invited per each screening session.
Evidence for re-organization of FTF consultations has
emerged from this poll and this applies to both newly diag-
nosed symptomatic breast cancers and post-operative
cases. According to the amended guidelines of the “the
COVID-19 Pandemic Breast Cancer Consortium”, in person
visits should be converted to telemedicine, whenever possi-
ble, unless there is clinical urgency for FTF consultation 33.
The COVID-19 pandemic has allowed widespread conver-
sion to telemedicine demonstrating its utility as an effective
tool for social distancing in the clinical setting and for
reducing outpatient workload without compromising opti-
mal care. In the current crisis, telemedicine can be used to
communicate both benign and malignant pathology results
and to initiate endocrine treatment as primary or adjuvant
therapy. Of course, reliable infrastructures should be avail-
able across the world, as well as trained staff, a validated
workflow and safe management of individual data34. The
quality of care in telemedicine should be comparable to in-
person care, although physical examination is necessarily
precluded. Nonetheless, the overall care process should not
be compromised in any way that might threaten patient
safety. Robust protocols must exist that permit discrimina-
tion between visits that can safely be performed in tele-
medicine and those mandating physical examination.
In some regions of the world affected by COVID-19 ,
local governments have opted for COVID-dedicated and
COVID-free/ light hospitals, for treatment of specific condi-
tions. For example, In the UK, USA and parts of Italy some
dedicated cancer hospitals have continued to offer oncolog-
ical care within standard timeframes and adhered to rou-
tine management protocols. A negative pharyngeal swab
before access to these facilities was essential and patients
were treated only if COVID-19 negative. In some institutions
cancer surgery was deferred for COVID -19 positive patients
pending resolution of symptoms and two subsequent nega-
tive swabs (COVID-free hospitals) while others reserved
clinical and operating areas for treatment of COVID-19 posi-
tive patients.
CONCLUSIONS
Approximately 150,000 new cases of breast cancer are diag-
nosed every month worldwide. Once screening has been
suspended and breast consultations reduced, a delays in
diagnosis of small screen-detected and some symptomatic
cancers might be expected. However any delays attribut-
able to COVID-19 are unlikely to have any prognostic impact
for these indolent slow growing tumours nor indeed for
cases of ‘over-diagnosis’. This is why in the post pandemic
phase criteria for prioritization will continue to be refined
and aid in selecting those patients who are appropriate can-
didates for primary surgery.
The unexpected contingency of COVID-19 should not
compromise the management of a potentially lethal disease
like breast cancer. The results of this survey highlight a
trend towards reduction of theatre lists and out-patient
facilities that is escalating across emergency phases. Our
survey shows that physicians individually can be reluctant
to abandon standards, change surgical priorities or escape
to alternative treatments until operating rooms are not
available. However, more restrictions or alternative strate-
gies are accepted as the situation worsens.
Access to cancer therapy should be managed in order to
offer a level of care as close as possible to the standards.
Now more than ever, multidisciplinary discussion regarding
priority for treatments on a case-by-case basis is highly rec-
ommended. Communication between surgical oncologist
and health-care authorities is largely awaited. Notwith-
standing the importance of control measures, breast cancer
surgery is not per se resource consuming and it should be
performed even with minimal capacity.
In this context, surgeons and health systems in general
are invited to be resilient. This means that: every strategy
to get the same surgical outcomes should be pursued; the
waiting times should be used to increase pre-habilitation;
observation or use of alternative therapeutic strategies
should be performed within randomized trials or under
strict surveillance.
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Figure 1. Operating room schedules distribution
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Figure 2. Changes in the OR schedule according to the ACS phase
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Figure 3. Organization of consultations/ long term follow-up visits
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Figure 4. Changes in the surgical priorities according to the ACS phase
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Figure 5. Cases that can be deferred distribution
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Figure 6. Changes in the alternative treatment approach according to the ACS phase
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